No. 11 of Korean new drug for B hepatitis approved.
Bukwang said that as of Nov. 13 the KFDA approved Lebovir 10mg cap (clevudine) for the treatment of chronic B hepatitis, which will become the number 11 of new drug solely developed by a Korean drug company, and the 4th innovative drug in the world.
Bukwang started its R&D in 1995 when ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
